|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
Stocks >> Stocks Details |
|
CRTX |
| |
|
|
|
|
|
CRITICAL THERAPEUTICS |
| |
Critical Therapeutics, Inc. is developing and
commercializing innovative products for respiratory, inflammatory and critical
care diseases. The Company owns worldwide rights to two FDA-approved drugs for
the prevention and chronic treatment of asthma in patients 12 years of age and
older: twice-daily ZYFLO CR(TM) (zileuton) extended-release tablets and ZYFLO®
(zileuton tablets).
Critical Therapeutics is working to develop products for
acute asthma attacks that lead patients to the emergency room and other urgent
care settings. The Company also is developing therapies directed toward the
body's inflammatory response. Critical Therapeutics is located in Lexington,
Mass. For more information, please visit www.crtx.com.
NEWS
CRITICAL THERAPEUTICS (CRTX)
05/31/2007 The FDA
approves ZYFLO CR™, the first extended -release leukotriene synthesis
inhibitor for the prophylaxis and chronic treatment of asthma in adults
and children 12 years of age and older.
|
| |
| |
| |
| |
| |
| |
|
| |
|
